Cerus (NASDAQ:CERS) Releases Quarterly Earnings Results, Meets Expectations

Cerus (NASDAQ:CERS) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01), FiscalAI reports. Cerus had a negative return on equity of 15.18% and a negative net margin of 4.41%.The business had revenue of $63.30 million for the quarter, compared to analysts’ expectations of $62.90 million.

Here are the key takeaways from Cerus’ conference call:

• Q2 product revenue rose 10% to $57.4 million, while first-half revenue increased 16% year over year. Cerus raised the low end of its 2026 product revenue guidance to $229 million–$231 million, implying 11%–12% annual growth.
• INTERCEPT fibrinogen complex (IFC) revenue grew approximately 40% excluding prior-period revenue, with demand up 43%; Cerus raised its 2026 IFC revenue outlook to $23 million–$25 million. The company cited growing hospital adoption, BCA collaboration, and the product’s immediate availability and five-day post-thaw shelf life.
• Cerus refinanced its debt, reducing the term loan by $30 million and expecting to lower annual interest expense by up to $3.5 million. Adjusted EBITDA remained positive for the ninth consecutive quarter, and management said it has a path toward GAAP profitability.
• Product gross margin declined to 51.4% from 55.2% a year earlier due to currency and inflationary pressures; management expects full-year 2026 margins to remain in the low 50% range. Operating cash flow was negative $2.7 million, primarily because of higher inventory supporting expected growth.
• The company submitted its INT200 platelet PMA to the FDA and could receive approval as early as the first half of 2027. Cerus also expects Phase III INTERCEPT red blood cell trial results in the fourth quarter and expanded its BARDA contract by nearly $22 million to support U.S. regulatory activities.

Cerus Price Performance

Cerus stock traded up $0.02 during midday trading on Thursday, reaching $2.89. 1,935,522 shares of the company were exchanged, compared to its average volume of 2,129,708. The firm’s 50-day simple moving average is $2.87 and its 200-day simple moving average is $2.43. Cerus has a 1 year low of $1.15 and a 1 year high of $3.47. The company has a market capitalization of $579.07 million, a price-to-earnings ratio of -57.80 and a beta of 1.77. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.06 and a current ratio of 1.63.

Analyst Ratings Changes

Several research firms have weighed in on CERS. Zacks Research raised Cerus from a “strong sell” rating to a “hold” rating in a report on Thursday, April 30th. BTIG Research upgraded shares of Cerus from a “neutral” rating to a “buy” rating and set a $4.00 price objective on the stock in a research report on Friday, May 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Cerus in a research note on Thursday, June 18th. Finally, Wall Street Zen upgraded shares of Cerus from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Cerus currently has a consensus rating of “Hold” and a consensus target price of $4.00.

Insider Activity at Cerus

In other news, CEO William Mariner Greenman sold 101,919 shares of Cerus stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $2.94, for a total transaction of $299,641.86. Following the completion of the sale, the chief executive officer directly owned 5,053,036 shares in the company, valued at $14,855,925.84. The trade was a 1.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Eric Bjerkholt sold 20,454 shares of the business’s stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $2.60, for a total transaction of $53,180.40. Following the completion of the transaction, the director directly owned 261,679 shares of the company’s stock, valued at approximately $680,365.40. This represents a 7.25% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 256,071 shares of company stock worth $747,894 over the last three months. Company insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC grew its position in shares of Cerus by 152.4% in the first quarter. Cubist Systematic Strategies LLC now owns 104,101 shares of the biotechnology company’s stock valued at $145,000 after purchasing an additional 62,854 shares during the period. AQR Capital Management LLC lifted its position in Cerus by 291.6% during the first quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company’s stock worth $1,986,000 after buying an additional 1,064,133 shares during the period. Millennium Management LLC boosted its stake in Cerus by 12.0% in the 1st quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company’s stock worth $4,479,000 after buying an additional 344,395 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Cerus in the 1st quarter worth about $32,000. Finally, Rhumbline Advisers grew its holdings in Cerus by 6.8% in the 2nd quarter. Rhumbline Advisers now owns 268,946 shares of the biotechnology company’s stock valued at $379,000 after buying an additional 17,039 shares during the period. Hedge funds and other institutional investors own 78.37% of the company’s stock.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.